GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...

PHILADELPHIA, PA — GSK plc (LSE/NYSE ... in reducing lower respiratory tract disease (LRTD) caused by respiratory syncytial ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

In its Q3 results, GSK , the first to receive U.S. approval for an RSV vaccine in May 2023, said its Arexvy vaccine added ...

Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months of 2024, compared the same period one year before. In a earnings report ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to infants and young children, RSV poses an even greater risk to older adults ...

MANILA, Philippines — Respiratory Syncytial Virus (RSV) is a common, contagious virus affecting the lungs and breathing ...

GSK accelerated respiratory syncytial virus--RSV--drug trials by two years through real-time location tracking of infectious diseases thanks to predictive data modelling, Walmsey adds.

Amongst the APEC countries and regions in the survey, hospitalisation costs per older adult in Singapore amounted to SGD ...

PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk Strategic ...